T1	Participants 66 89	small-cell lung cancer:
T2	Participants 400 531	Patients with extensive SCLC with a Karnofsky performance score (KPS) > or = 50 and adequate renal function and bone marrow reserve
T3	Participants 547 575	Patients with CNS metastases
T4	Participants 980 992	171 patients